



US005902821A

United States Patent [19]
Lukas-Laskey et al.

[11] Patent Number: 5,902,821

[45] Date of Patent: May 11, 1999

[54] USE OF CARBAZOLE COMPOUNDS FOR
THE TREATMENT OF CONGESTIVE HEART
FAILURE

[75] Inventors: Mary Ann Lukas-Laskey, Rosemont;
Robert Ruffolo, Jr., Spring City; Neil
Shusterman, Wynnewood, all of Pa.;
Gisbert Sponer, Laudenbach; Klaus
Strein, Hemsbach, both of Germany

[73] Assignee: Boehringer Mannheim
Pharmaceuticals Corporation Smith
Kline Corporation Limited
Partnership No. 1, Gaithersburg, Md.

[21] Appl. No.: 08/875,603

[22] PCT Filed: Feb. 7, 1996

[86] PCT No.: PCT/EP96/00498

§ 371 Date: Dec. 29, 1997

§ 102(e) Date: Dec. 29, 1997

[87] PCT Pub. No.: WO96/24348

PCT Pub. Date: Aug. 15, 1996

[30] Foreign Application Priority Data

Feb. 8, 1995 [DE] Germany 195 03 995

[51] Int. Cl.⁶ A61K 31/40

[52] U.S. Cl. 514/411

[58] Field of Search 514/411

[56] References Cited

U.S. PATENT DOCUMENTS

4,888,179 12/1989 Appelgren et al. 424/480
5,308,862 5/1994 Ohlstein 514/411
5,312,828 5/1994 Finkelstein et al. 514/381

OTHER PUBLICATIONS

J. of Cardiovascular Pharm; Senior, et al., "Effects of
Carvedilol on Ventricular Arrhythmias", 1992, vol. 19,
(Suppl. 1): pp. S117-S121.

J. of Cardiovascular Pharm; DasGupta, et al., "The Effects
of Intravenous Carvedilol, A New Multiple Action Vasodila-
tory β -Blocker, in Congestive Heart Failure", 1991, vol. 18,
(Suppl. 1): pp. S12-S16.

American J. of Cardiology; DasGupta, et al., "Value of
Carvedilol in Congestive Heart Failure Secondary to Coro-
nary Artery Disease", 1990, vol. 66, pp. 1118-1123.

Z. Kardiol; A. Buchwald, et al., "Acute Hemodynamic
Effects of the Beta-blocker Carvedilol in Heart Failure",
1990, vol. 79, No. 6, pp. 424-428.

JACC; DiLenarda, et al., "Acute Hemodynamic Effects of
Carvedilol Versus Metoprolol In Idiopathic Dilated Cardi-
omyopathy", 1991, vol. 17, No. 2, Abstract 142A.

Frontiers in CHF; D. Tepper, "Multicenter Oral Carvedilol
Heart Failure Assessment", 1996, vol. 2, No. 1, pp. 39-40.

J. of Cardiovascular Pharm; DasGupta, et al., 1992, vol. 19,
(Suppl. 1): pp. S62-S67.

J. of Hypertension; C. Rosendorff, "Beta-blocking agents
with vasodilator activity", 1993, vol. 11, (Suppl. 4): pp.
S37-S40.

Cardiology; J. Lessem, et al., "Development of a Multi-
action Beta-blocker", 1993, vol. 82, (Suppl. 3): pp. 50-58.
Drug Safety; W.J. Louis, et al., "A Risk-Benefit Assessment
of Carvedilol in the Treatment of Cardiovascular Disorders",
1994, vol. 11, No. 2, pp. 86-93.

1994 American Heart Association, Inc., "A Randomized
Trial of β -Blockade in Heart Failure", Circulation 90(4),
Oct. 1994, pp. 1765-1773.

Waagstein et al., The Lancet, vol. 342, Dec. 11, 1993,
"Beneficial effects of metoprolol in idiopathic dilated car-
diomyopathy", pp. 1441-1446.

Ruffolo et al., Cardiology 1993; 82(suppl 3):24-28, "Car-
dioprotective Potential of Carvedilol", pp. 24-28.

Feuerstein et al., Journal of Hypertension 1993, vol.
11(suppl 4), "Myocardial protection by the novel vasodi-
lating beta-blocker, carvedilol; potential relevance of anti-
-oxidant activity".

Feuerstein et al., Journal of Cardiovascular Pharmacology,
19(suppl. 1) S138-141, "Myocardial Protection with
Carvedilol"(1992).

DiBianco et al., The New England Journal of Medicine, vol.
320, Mar. 16, 1989, No. 11, "A comparison of oral mil-
rinone, digoxin, and their combination in the treatment of
patients . . .", pp. 677-678.

Cohn et al., The New England Journal of Medicine, vol. 313,
No. 24, "Effect of vasodilator therapy on mortality in
chronic congestive heart failure", Jun., 1986, pp.
1547-1552.

McTavish et al., Drugs, 45(2): 232-258, 1993, "Carvedilol,
A review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic efficacy".

Drugs; McTavish, et al., "Carvedilol—A Review of its
Pharmacodynamic and Pharmacokinetic Properties, and
Therapeutic Efficacy", 1993, vol. 45, No. 2, pp. 232-258.

Circulation; H. Krum, et al., "Effects of Carvedilol, a
Vasodilator- β -Blocker, in Patients with Congestive Heart
Failure Due to Ischemic Heart Disease", 1995, vol. 92, No.
2, pp. 212-218.

CBS-TV; CBS Evening News, Transcript, Jan. 27, 1993,
6:30-7:00pm.

CNBC; Steals and Deals, Transcript, Jan. 29, 1993, 8:30pm.
Circulation; DasGupta, et al., 1989, vol. 80, No. 4, (Suppl.
II): pp. 116-117.

Drugs of Today; Ruffolo, et al., "Carvedilol (Kredex): A
Novel Multiple Action Cardiovascular Agent", 1991, vol.
27, No. 7, pp. 465-492.

Primary Examiner—Phyllis G. Spivack

Attorney, Agent, or Firm—Nikaido, Marmelstein, Murray &
Oram LLP

[57]

ABSTRACT

A method of treatment using carvedilol is disclosed, wherein
the carvedilol decreases the mortality caused by congestive
heart failure in patients. The patients are titrated with low
amounts of carvedilol, with the initial titration dosage being
only 10 to 30% of the daily maintenance dose.

11 Claims, No Drawings